NEW YORK – Solid IO on Monday said it raised €800,000 ($840,000) to advance its tumor-on-a-chip technology for personalized and immunotherapy treatments in cancer.
Helsinki-based Solid IO's platform recapitulates the tumor microenvironment, allowing doctors to obtain accurate, real-time predictions of treatment response to guide individualized therapy selection for patients. It can also be used in clinical studies to stratify patients within a trial, validate biomarkers, and model treatment response.
Nordic Science Investments led the financing, and BSV Ventures, Helsinki University Funds, and a private European investor contributed.
"Every cancer patient deserves a treatment plan based on their unique biology, adapting throughout the treatment journey," Solid IO CEO and Cofounder Noora Hujala said in a statement. "We are eliminating trial-and-error in cancer immunotherapy by bringing patient-specific tumor models into clinical use — this is the next evolution in precision oncology."